31.5.2017 18:39 | Business Wire
The International WELL Building Institute™ Announces WELL Portfolio™
The International WELL Building Institute™ (IWBI™) announced today that CBRE Group, Inc., Hines , and Lendlease are among leading global developers collaborating with IWBI to deliver WELL Portfolio™, a new cost-effective, existing building portfolio certification pathway within the WELL Building Standard™ (WELL). This new pathway will reward a commitment to ongoing enhancements to existing buildings, with specific focus on policies, programs, procurement guidelines, and plans that can be applied across a portfolio of buildings.
A roundtable of those who have expressed interest in the WELL Portfolio concept will be held in New York City on June 15. Those committing to piloting a sample portfolio of qualifying buildings in this first phase will join a Portfolio Advisory to directly inform the pathway’s development.
“We know that when building owners, operators, and corporate tenants look across their portfolios, they typically shift their parameters one policy at a time, not a building at a time,” said Rick Fedrizzi, chairman and CEO of IWBI . “We believe this new approach can introduce immediate and measurable performance improvements and allow projects to earn recognition for their achievements, reducing fees and overall costs in the process.”
“Hines is very interested in this approach of certifying health and wellness attributes in existing buildings, not only development,” said Hines Innovation Officer Charlie Kuntz . “With a large global development and property management portfolio, we want to build on our sustainability commitment in this leadership-defining area.”
“Global third-party sustainability indices and benchmarking tools like WELL have helped institutional investors make informed investment decisions and improve their portfolios,” said Brian Long, group head of safety and sustainability at Lendlease . “While focus has traditionally been on achieving positive environmental outcomes in buildings, greater focus is now on human health and wellness outcomes. Lendlease will continue to do both across our portfolio, providing competitive differentiation and longer-term value for our clients.”
“We are pleased to assist with the development of a comprehensive portfolio-wide approach for WELL Certification and believe this will be an important addition to ongoing efforts to introduce this standard to a wider marketplace,” said David L. Pogue, global director of corporate responsibility, CBRE.
The comprehensive scientific evidence that lays the groundwork for wellness decisions is indisputable and growing every day, further supporting the value of WELL Certification to companies looking to improve employee productivity and engagement, lower absenteeism, and potentially reduce insurance health care spend.
“WELL Portfolio is a direct response to owners and operators who have shared with us their desire to rapidly incorporate proven, science-based practices across all their existing buildings, and to have their work third-party verified. We’re looking forward to their input on the best ways to move these practices rapidly to scale,” Fedrizzi added, “because improving health and wellness through better buildings is sustainability’s second wave.”
About the WELL Building Standard™
The WELL Building Standard™ (WELL™) is a performance-based system for measuring, certifying, and monitoring features of the built environment that impact the health and wellness of the people who live, work, and learn in the buildings. WELL focuses on seven categories of building performance: air, water, nourishment, light, fitness, comfort, and mind. The WELL Building Standard is grounded in evidence-based research that demonstrates the connection between the buildings where people spend approximately 90 percent of their time and those buildings’ health and wellness impacts on those who use them. The WELL Building Standard is administered by the International WELL Building Institute™ and third party certified by Green Business Certification Inc. (GBCI). www.wellcertified.com
About the International WELL Building Institute™
The International WELL Building Institute™ (IWBI™) is a public benefit corporation whose mission is to improve human health and wellness through the built environment. Public benefit corporations like IWBI are an emerging U.S. structure for corporations committed to balancing public benefits with profitability – harnessing the power of private capital for greater good. IWBI administers the WELL Building Standard™ (WELL™) – a performance-based system for measuring, certifying, and monitoring features of buildings that impact the health and wellness of the people who live, work, and learn in them. It also supports the growing number of professionals who seek WELL accreditation, as administered by GBCI. www.wellcertified.com
# # #
IWBI Press Contact:
Callie Stanton, 646-654-3438
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Ved at skrive dig op her, vil du modtage pressemeddelelser på mail når de udsendes. Indtast din mail og følg instruktionerne. Det er ligeså let at melde sig fra igen.
Flere pressemeddelelser fra Business Wire
NY-IFF/ZOOMESSENCE23.6.2017 14:48 | pressemeddelelse
IFF and ZoomEssence Announce Settlement of Lawsuit
BIOGEN23.6.2017 13:57 | pressemeddelelse
Biogen’s IMRALDI®, an Adalimumab Biosimilar Candidate Referencing Humira®, Granted Positive Opinion by Committee for Medicinal Products for Human Use
EUSA-PHARMA23.6.2017 13:38 | pressemeddelelse
EUSA Pharma Receive Positive Opinion from The CHMP For tivozanib For The First-Line Treatment of Advanced Renal Cell Carcinoma In The European Union
CA-GILEAD-SCIENCES,-INC.23.6.2017 13:37 | pressemeddelelse
European CHMP Adopts Positive Opinion for Gilead’s Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) for the Treatment of All Chronic Hepatitis C Genotypes
SAMSUNG-BIOEPIS23.6.2017 13:32 | pressemeddelelse
Samsung Bioepis' Imraldi® (Adalimumab) Recommended for Approval by European Medicines Agency
MA-BLUEBIRD-BIO23.6.2017 13:02 | pressemeddelelse
bluebird bio Presents New Data from HGB-205 Study of LentiGlobinTM Drug Product in Patients with Transfusion-Dependent β-Thalassemia (TDT) and Severe Sickle Cell Disease (SCD) at European Hematology Association (EHA) Annual Meeting
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum